TransADMET Mouse Programme

Taconic's transADMET Mouse Programme helps transform compound development by better predicting ADMET in humans.

Current preclinical models can be poorly predictive of absorption, distribution, metabolism, excretion and toxicology (ADMET) in humans. This inability to translate animal results to man is driven by profound interspecies differences in the levels and functions of proteins involved in ADMET and it is a major reason for development failure in the pharmaceutical and chemical industries.

In response, CXR Biosciences and TaconicArtemis have developed the transADMET programme via an ITI Life Sciences-sponsored research programme. Key murine ADMET genes have either been exchanged for their human counterparts or knocked out for use as controls.

Once all the models are commercially available, they will be packaged in three panels representing critical pathways in compound metabolism and disposition:

• The receptor panel
• The cytochrome P450 panel
• The drug transporter panel